普伐他汀在孕期应用的现状及前景  

Current status and prospect of pravastatin in pregnancy

作　　者：林晓虹 王冬昱[1] 沈丽霞[1] 王子莲[1] Xiaohong Lin;Dongyu Wang;Lixia Shen;Zilian Wang(Department of Obstetrics,the First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China)

机构地区：[1]中山大学附属第一医院产科,广州510080

出　　处：《中华围产医学杂志》2023年第8期696-700,共5页Chinese Journal of Perinatal Medicine

基　　金：国家重点研发计划(2021YFC2700700)。

摘　　要：长期以来他汀类降脂药如普伐他汀等禁用于孕产妇,但近年来其在孕期应用的安全性逐渐获得了一些临床证据。研究发现普伐他汀可改善血管生成失衡、减轻血管炎症,对胎盘和母体血管功能障碍相关疾病,如子痫前期、胎儿生长受限及妊娠合并抗磷脂综合征等可产生有益作用,但普及应用仍需更多的安全证据以及更大样本的人体试验数据支持。本文即综述普伐他汀在孕期应用的现状及前景。Cholesterol-lowing statins such as pravastatin have been contraindicated in pregnant women for a long time,but recent clinical evidence has demonstrated its safety.Studies have found that pravastatin can correct the imbalance in angiogenesis,reduce vascular inflammation and improve the conditions in patients with placental and maternal vascular dysfunction-related diseases,such as preeclampsia,fetal growth restriction and antiphospholipid syndrome.However,universal administration of pravastatin in pregnancy still requires more evidence on its safety from human clinical trials with larger sample sizes.This article reviews the current situation and prospect of pravastatin in pregnancy.

关 键 词：普伐他丁 妊娠并发症 先兆子痫 胎儿生长迟缓 

分 类 号：R714[医药卫生—妇产科学]